Taken together, our findings showed that CD39+CD103+ TRM cells in high-grade endometrial cancer are polyfunctional T cells with a reactivation-responsive repertoire, despite their exhausted phenotype, and these TRM express a variety of immune checkpoints. This evidence concerns the gene ENTPD1 and endometrial cancer.